BIOSPECIFICS TECHNOLOGIES CORP (BSTC.OB) is a publicly traded company in the Unknown sector. Across all available filings, 4 corporate insiders have executed 44 transactions totaling $25.7M, demonstrating a bearish sentiment with -$25.5M in net insider flow. The most recent transaction on Jun 3, 2008 involved a purchase of 1,200 shares valued at $13.5K.
No significant insider buying has been recorded for BSTC.OB in the recent period.
No significant insider selling has been recorded for BSTC.OB in the recent period.
Based on recent SEC filings, insider sentiment for BSTC.OB is bearish with an Insider Alignment Score of 0/100 and a net flow of -$25.5M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at BIOSPECIFICS TECHNOLOGIES CORP (BSTC.OB) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 4 insiders are actively trading BSTC.OB stock, having executed 44 transactions in the past 90 days. The most active insider is Toby Wegman (Executive), who has made 9 transactions totaling $8.7M.
Get notified when executives and directors at BSTC.OB file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jun 3, 2008 | Kenneth Vogel Jeffrey | Executive | Purchase | 1,200 | $11.25 | $13.5K | |
| May 30, 2008 | Kenneth Vogel Jeffrey | Executive | Purchase | 700 | $12.00 | $8.4K | |
| May 22, 2008 | Kenneth Vogel Jeffrey | Executive | Purchase | 1,500 | $12.00 | $18.0K | |
| May 21, 2008 | Kenneth Vogel Jeffrey | Executive | Purchase | 140 | $12.00 | $1.7K | |
| May 19, 2008 | Kenneth Vogel Jeffrey | Executive | Purchase | 350 | $10.25 | $3.6K | |
| Apr 7, 2008 | Wegman Toby | Executive | Sale | 200,000 | $11.00 | $2.2M | Large |
| Apr 7, 2008 | Wegman Thomas | Executive | Sale | 200,000 | $11.00 | $2.2M | Large |
| Apr 7, 2008 | Edwin H. Wegman Estate Of | Executive | Sale | 200,000 | $11.00 | $2.2M | Large |
| Apr 7, 2008 | Wegman Toby | Executive | Sale | 200,000 | $11.00 | $2.2M | Large |
| Apr 7, 2008 | Wegman Thomas | Executive | Sale | 200,000 | $11.00 | $2.2M | Large |
| Apr 7, 2008 | Edwin H. Wegman Estate Of | Executive | Sale | 200,000 | $11.00 | $2.2M | Large |
| Mar 20, 2008 | Kenneth Vogel Jeffrey | Executive | Purchase | 500 | $10.00 | $5.0K | |
| Mar 19, 2008 | Kenneth Vogel Jeffrey | Executive | Purchase | 1,500 | $10.10 | $15.2K | |
| Mar 19, 2008 | Kenneth Vogel Jeffrey | Executive | Purchase | 500 | $10.00 | $5.0K | |
| Feb 1, 2008 | Wegman Toby | Executive | Sale | 100,000 | $12.00 | $1.2M | Large |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 15 | $25.6M | 97.9% |
Exercise (Options)(X) | 6 | $447.0K | 1.7% |
Purchase(P) | 17 | $103.9K | 0.4% |
Other(J) | 6 | $0 | 0.0% |
Insider selling pressure at BIOSPECIFICS TECHNOLOGIES CORP has increased, with 4 insiders executing 44 transactions across all time. Total sales of $25.6M significantly outpace purchases of $103.9K, resulting in a net outflow of $25.5M. This selling activity appears largely discretionary, which may warrant closer attention from investors.